BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38 Suppl 1:S54-S68. [PMID: 12591186 DOI: 10.1016/s0168-8278(02)00430-0] [Cited by in Crossref: 182] [Cited by in F6Publishing: 29] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Addley J, Tham TC, Cash WJ. Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc. 2012;4:281-289. [PMID: 22816007 DOI: 10.4253/wjge.v4.i7.281] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
2 Santambrogio R, Opocher E, Costa M, Bruno S, Ceretti AP, Spina GP. Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World J Gastroenterol 2006;12:6331-8. [PMID: 17072957 DOI: 10.3748/wjg.v12.i39.6331] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
3 Zhang YF, Ji H, Lu HW, Lu L, Wang L, Wang JL, Li YM. Comparison of simplified and traditional pericardial devascularisation combined with splenectomy for the treatment of portal hypertension. World J Clin Cases. 2018;6:99-109. [PMID: 29988874 DOI: 10.12998/wjcc.v6.i6.99] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Hu LS, George J, Wang JH. Current concepts on the role of nitric oxide in portal hypertension. World J Gastroenterol. 2013;19:1707-1717. [PMID: 23555159 DOI: 10.3748/wjg.v19.i11.1707] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
5 Biecker E. Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol. 2013;19:5035-5050. [PMID: 23964137 DOI: 10.3748/wjg.v19.i31.5035] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
6 Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol. 2017;9:270-277. [PMID: 28261384 DOI: 10.4254/wjh.v9.i5.270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Vilas-Boas WW, Ribeiro-Oliveira A Jr, Ribeiro Rda C, Vieira RL, Almeida J, Nadu AP, Simões e Silva AC, Santos RA. Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World J Gastroenterol 2008;14:6824-30. [PMID: 19058308 DOI: 10.3748/wjg.14.6824] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
8 Sarin SK, Mishra SR, Sharma P, Sharma BC, Kumar A. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial. Hepatol Int 2013;7:248-56. [PMID: 26201639 DOI: 10.1007/s12072-012-9353-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
9 Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573-82. [PMID: 19724251 DOI: 10.1038/nrgastro.2009.149] [Cited by in Crossref: 363] [Cited by in F6Publishing: 284] [Article Influence: 30.3] [Reference Citation Analysis]
10 Elwan N, Salah R, Hamisa M, Shady E, Hawash N, Abd-Elsalam S. Evaluation of portal pressure by doppler ultrasound in patients with cirrhosis before and after simvastatin administration - a randomized controlled trial. F1000Res 2018;7:256. [PMID: 29707200 DOI: 10.12688/f1000research.13915.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Ding SH, Liu J, Wang JP. Efficacy of beta-adrenergic blocker plus 5-isosorbide mononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis. World J Gastroenterol. 2009;15:2151-2155. [PMID: 19418589 DOI: 10.3748/wjg.15.2151] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
12 Biecker E. Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol. 2013;2013:541836. [PMID: 27335828 DOI: 10.1155/2013/541836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Krige JE, Kotze UK, Distiller G, Shaw JM, Bornman PC. Predictive factors for rebleeding and death in alcoholic cirrhotic patients with acute variceal bleeding: a multivariate analysis. World J Surg. 2009;33:2127-2135. [PMID: 19672651 DOI: 10.1007/s00268-009-0172-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
14 Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. Curr Treat Options Gastroenterol 2018;16:226-40. [PMID: 29572618 DOI: 10.1007/s11938-018-0180-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
15 Dib N, Oberti F, Calès P. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ 2006;174:1433-43. [PMID: 16682712 DOI: 10.1503/cmaj.051700] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
16 Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62:S121-S130. [PMID: 25920081 DOI: 10.1016/j.jhep.2015.01.003] [Cited by in Crossref: 112] [Cited by in F6Publishing: 82] [Article Influence: 22.4] [Reference Citation Analysis]
17 Reiberger T, Bucsics T, Paternostro R, Pfisterer N, Riedl F, Mandorfer M. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? Curr Hepatol Rep. 2018;17:301-315. [PMID: 30546995 DOI: 10.1007/s11901-018-0420-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Samonakis DN, Triantos CK, Thalheimer U, Patch DW, Burroughs AK. Management of portal hypertension. Postgrad Med J. 2004;80:634-641. [PMID: 15537846 DOI: 10.1136/pgmj.2004.020446] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
19 Ponziani FR, De Stefano V, Gasbarrini A. Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. Mediterr J Hematol Infect Dis 2009;1:e2009033. [PMID: 21415961 DOI: 10.4084/MJHID.2009.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 El-Tawil AM. Trends on gastrointestinal bleeding and mortality: where are we standing? World J Gastroenterol 2012;18:1154-8. [PMID: 22468077 DOI: 10.3748/wjg.v18.i11.1154] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
21 Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
22 Londoño MC, Cárdenas A, Guevara M, Quintó L, de Las Heras D, Navasa M, Rimola A, Garcia-Valdecasas JC, Arroyo V, Ginès P. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283-1290. [PMID: 17452425 DOI: 10.1136/gut.2006.102764] [Cited by in Crossref: 136] [Cited by in F6Publishing: 103] [Article Influence: 9.7] [Reference Citation Analysis]
23 Aller MA, Vara E, Garcia C, Palma MD, Arias JL, Nava MP, Arias J. Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. Mediators Inflamm. 2005;2005:101-111. [PMID: 16030393 DOI: 10.1155/mi.2005.101] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
24 Donati G, Angeletti A, Gasperoni L, Piscaglia F, Croci Chiocchini AL, Scrivo A, Natali T, Ullo I, Guglielmo C, Simoni P, Mancini R, Bolondi L, La Manna G. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). J Nephrol 2021;34:77-88. [PMID: 32710265 DOI: 10.1007/s40620-020-00799-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol 2010;16:5139-47. [PMID: 21049548 DOI: 10.3748/wjg.v16.i41.5139] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
26 Maruyama H, Okugawa H, Kobayashi S, Yoshizumi H, Takahashi M, Ishibashi H, Yokosuka O. Non-invasive portography: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis. Br J Radiol. 2012;85:587-595. [PMID: 21343319 DOI: 10.1259/bjr/25522379] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
27 Thalheimer U, Mela M, Patch D, Burroughs AK. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. Gut. 2004;53:143-148. [PMID: 14684589 DOI: 10.1136/gut.53.1.143] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
28 Reverter E, Mesonero F, Seijo S, Martínez J, Abraldes JG, Peñas B, Berzigotti A, Deulofeu R, Bosch J, Albillos A, García-Pagán JC. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. Am J Gastroenterol 2015;110:985-92. [PMID: 26077176 DOI: 10.1038/ajg.2015.185] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
29 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]